Specialty drugs are adding to employer health care bills. MiBiz senior writer, Mark Sanchez, asks if this is increasing costs or creating high value?
MiBiz with Mark Sanchez
Facebook Twitter LinkedIn Email
Your browser doesn’t support HTML5 audio